
Asia Pacific Anti-Obesity Drugs Market Report and Forecast 2024-2032
Description
Asia Pacific Anti-Obesity Drugs Market Report and Forecast 2024-2032
Asia Pacific Anti-Obesity Drugs Market Report and Forecast 2024-2032
Asia Pacific Anti-Obesity Drugs Market Outlook
The anti-obesity drugs market size was valued at USD 2.5 billion in 2023, with Asia Pacific holding a significant market share. The market is driven by the rising prevalence of obesity. It is expected to grow at a CAGR of 11.6% during the forecast period of 2024-2032, with the values likely to attain USD 6.3 billion by 2032.
Key Takeaways
- It is reported that the obesity prevalence rate in the Asia Pacific region is increasing rapidly. This surge in obesity rates is expected to augment the need for effective weight management solutions including anti-obesity drugs.
- In January 2024 , it was reported that Chinese biotechnology company Innovent Biologics Inc. and Eli Lilly and Company’s anti-obesity drug mazdutide achieved positive Phase III results, with data showing a significant reduction in body weight by week 32 and a majority of patients undergoing weight loss of 5% or more. The development of such innovative anti-obesity medications with higher efficacy and fewer side effects is expected to elevate the Asia Pacific anti-obesity drugs market value.
- One of the major market trends is the rising development of biosimilar drugs to provide cost-effective alternatives for weight management. For instance, in April 2024, Hangzhou Jiuyuan Gene Engineering Co., Ltd. revealed that it is seeking marketing approval for Jiyoutai, the first biosimilar drug expected to provide strong competition to Novo Nordisk’s weight-loss and diabetes drugs portfolio in China.
Anti-obesity drugs comprise medications that aid in reducing or controlling the weight of an individual such as appetite suppressants, fat absorption inhibitors, and metabolic enhancers. The rising public awareness regarding the risks associated with obesity like cardiovascular diseases, hypertension, and diabetes, is prompting obese patients to seek appropriate treatments including weight loss drugs. Further, increased initiatives from the government to combat obesity are expected to drive the Asia Pacific anti-obesity drugs market growth.
The high prevalence of obesity directly influences the market demand for anti-obesity drugs. It is reported that the obesity prevalence rate in the Asia Pacific region is growing rapidly. In China, over 50% of adults and nearly 20% of school-age children are experiencing overweight conditions . This surge in obesity rates can be attributed to changing dietary habits and increased sedentary lifestyles, which is expected to augment the need for effective weight management solutions, thereby boosting the market share of anti-obesity drugs.
One of the major Asia Pacific anti-obesity drugs market trends is the rising development of biosimilar drugs to provide cost-effective alternatives for weight management. For instance, in April 2024 , a Chinese biopharmaceutical company Hangzhou Jiuyuan Gene Engineering Co., Ltd. revealed that it is seeking marketing approval for Jiyoutai (a biosimilar to semaglutide), the first biosimilar drug expected to provide strong competition to Novo Nordisk’s weight-loss and diabetes drugs portfolio in China. The increased access to a wide range of anti-obesity drugs in the region is anticipated to propel the market growth.
The Asia Pacific anti-obesity drugs market share is positively influenced by the ongoing research in obesity treatment solutions which is leading to the introduction of novel anti-obesity drugs. In January 2024 , it was reported that Innovent Biologics Inc. (a Chinese biotechnology company) and Eli Lilly and Company’s anti-obesity drug mazdutide (a dual glucagon-like peptide-1 (GLP-1) glucagon receptor agonist) achieved positive Phase III results. In the GLORY-1 trial, the drug met both of its primary endpoints, with data showing a significant reduction in body weight by week 32 and a majority of patients undergoing weight loss of 5% or more. The development of such innovative anti-obesity medications with higher efficacy and fewer side effects is expected to elevate the market value.
Asia Pacific Anti-Obesity Drugs Market Segmentation
Market Breakup by Drugs
- Semaglutide
- Phentermine/Topiramate
- Naltrexone/Bupropion
- Liraglutide
- Gelesis 100
- Orlistat
- Phentermine
- Methamphetamine
- Tirzepatide
- Amphetamine
- GLP-1 Receptor Agonist
- Lipase Inhibitor
- Centrally Acting Drugs
- Peripherally Acting Drugs
- Oral
- Subcutaneous
- Prescription Drugs
- Over The Counter Drugs
- Hospital Pharmacies
- Drug Store and Retail Pharmacies
- Online Pharmacies
- China
- Japan
- ASEAN
- Australia
- India
- Other
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- VIVUS Inc.
- Pfizer, Inc.
- Novo Nordisk
- Bayer AG
- F Hoffmann-La Roche
- Glaxosmithkline
- Arena Pharmaceuticals
- Eisai Co. Ltd
- Takeda Pharmaceutical Company
- Nalpropion Pharmaceuticals Inc.
FAQs
- What is the Asia Pacific anti-obesity drugs market forecast outlook for 2024-2032?
- What are the major factors aiding the Asia Pacific anti-obesity drugs market demand?
- What are the major Asia Pacific anti-obesity drugs market trends?
- What is the market segmentation based on the drugs?
- What are the various drug classes available in the market?
- What is the market breakup by mechanism of action?
- What is the market segmentation based on the route of administration?
- What is the market segmentation based on the prescription type?
- What are the major distribution channels of anti-obesity drugs?
- What is the market segmentation by countries?
- Who are the key players involved in the Asia Pacific anti-obesity drugs market?
Meta description
Asia Pacific anti-obesity drugs market is poised for growth, driven by the expansion of the global market, which was valued at USD 2.5 billion in 2023 and is projected to grow at a CAGR of 10.70% during the forecast period of 2024-2032.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Asia Pacific Anti-Obesity Drugs Market Overview
- 3.1 Asia Pacific Anti-Obesity Drugs Market Historical Value (2017-2023)
- 3.2 Asia Pacific Anti-Obesity Drugs Market Forecast Value (2024-2032)
- 4 Asia Pacific Anti-Obesity Drugs Market Landscape*
- 4.1 Asia Pacific Anti-Obesity Drugs Market: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Asia Pacific Anti-Obesity Drugs Market: Product Landscape
- 4.2.1 Analysis by Product
- 4.2.2 Analysis by Material
- 4.2.3 Analysis by Type
- 5 Asia Pacific Anti-Obesity Drugs Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Analysis
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Asia Pacific Anti-Obesity Drugs Market Segmentation (2017-2032)
- 6.1 Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Drugs
- 6.1.1 Market Overview
- 6.1.2 Semaglutide
- 6.1.3 Phentermine/Topiramate
- 6.1.4 Naltrexone/Bupropion
- 6.1.5 Liraglutide
- 6.1.6 Gelesis 100
- 6.1.7 Orlistat
- 6.1.8 Phentermine
- 6.1.9 Methamphetamine
- 6.1.10 Tirzepatide
- 6.2 Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Drug Class
- 6.2.1 Market Overview
- 6.2.2 Amphetamine
- 6.2.3 GLP-1 receptor agonist
- 6.2.4 Lipase Inhibitor
- 6.3 Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
- 6.3.1 Market Overview
- 6.3.2 Centrally Acting Drugs
- 6.3.3 Peripherally Acting Drugs
- 6.4 Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Route of Administration
- 6.4.1 Market Overview
- 6.4.2 Oral
- 6.4.3 Subcutaneous
- 6.5 Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Prescription Type
- 6.5.1 Market Overview
- 6.5.2 Prescription Drugs
- 6.5.3 Over The Counter Drugs
- 6.6 Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
- 6.6.1 Market Overview
- 6.6.2 Hospital Pharmacies
- 6.6.3 Drug Store & Retail Pharmacies
- 6.6.4 Online Pharmacies
- 6.7 Asia Pacific Anti-Obesity Drugs Market (2017-2032) by Countries
- 6.7.1 Market Overview
- 6.7.2 China
- 6.7.3 Japan
- 6.7.4 ASEAN
- 6.7.5 Australia
- 6.7.6 India
- 6.7.7 Others
- 7 China Anti- Obesity Drugs Market (2017-2032)
- 7.1 China Anti-Obesity Drugs Market (2017-2032) by Drugs
- 7.1.1 Market Overview
- 7.1.2 Semaglutide
- 7.1.3 Phentermine/Topiramate
- 7.1.4 Naltrexone/Bupropion
- 7.1.5 Liraglutide
- 7.1.6 Gelesis 100
- 7.1.7 Orlistat
- 7.1.8 Phentermine
- 7.1.9 Methamphetamine
- 7.1.10 Tirzepatide
- 7.2 China Anti-Obesity Drugs Market (2017-2032) by Drug Class
- 7.2.1 Market Overview
- 7.2.2 Market Overview
- 7.2.3 Amphetamine
- 7.2.4 GLP-1 receptor agonist
- 7.2.5 Lipase Inhibitor
- 7.3 China Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
- 7.3.1 Market Overview
- 7.3.2 Centrally Acting Drugs
- 7.3.3 Peripherally Acting Drugs
- 7.4 China Anti-Obesity Drugs Market (2017-2032) by Route of Administration
- 7.4.1 Market Overview
- 7.4.2 Oral
- 7.4.3 Subcutaneous
- 7.5 China Anti-Obesity Drugs Market (2017-2032) by Prescription Type
- 7.5.1 Market Overview
- 7.5.2 Prescription Drugs
- 7.5.3 Over The Counter Drugs
- 7.6 China Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
- 7.6.1 Market Overview
- 7.6.2 Hospital Pharmacies
- 7.6.3 Drug Store & Retail Pharmacies
- 7.6.4 Online Pharmacies
- 8 Japan Anti- Obesity Drugs Market (2017-2032)
- 8.1 Japan Anti-Obesity Drugs Market (2017-2032) by Drugs
- 8.1.1 Market Overview
- 8.1.2 Semaglutide
- 8.1.3 Phentermine/Topiramate
- 8.1.4 Naltrexone/Bupropion
- 8.1.5 Liraglutide
- 8.1.6 Gelesis 100
- 8.1.7 Orlistat
- 8.1.8 Phentermine
- 8.1.9 Methamphetamine
- 8.1.10 Tirzepatide
- 8.2 Japan Anti-Obesity Drugs Market (2017-2032) by Drug Class
- 8.2.1 Market Overview
- 8.2.2 Market Overview
- 8.2.3 Amphetamine
- 8.2.4 GLP-1 receptor agonist
- 8.2.5 Lipase Inhibitor
- 8.3 Japan Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
- 8.3.1 Market Overview
- 8.3.2 Centrally Acting Drugs
- 8.3.3 Peripherally Acting Drugs
- 8.4 Japan Anti-Obesity Drugs Market (2017-2032) by Route of Administration
- 8.4.1 Market Overview
- 8.4.2 Oral
- 8.4.3 Subcutaneous
- 8.5 Japan Anti-Obesity Drugs Market (2017-2032) by Prescription Type
- 8.5.1 Market Overview
- 8.5.2 Prescription Drugs
- 8.5.3 Over The Counter Drugs
- 8.6 Japan Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
- 8.6.1 Market Overview
- 8.6.2 Hospital Pharmacies
- 8.6.3 Drug Store & Retail Pharmacies
- 8.6.4 Online Pharmacies
- 9 ASEAN Anti-Obesity Drugs Market (2017-2032)
- 9.1 ASEAN Anti-Obesity Drugs Market (2017-2032) by Drugs
- 9.1.1 Market Overview
- 9.1.2 Semaglutide
- 9.1.3 Phentermine/Topiramate
- 9.1.4 Naltrexone/Bupropion
- 9.1.5 Liraglutide
- 9.1.6 Gelesis 100
- 9.1.7 Orlistat
- 9.1.8 Phentermine
- 9.1.9 Methamphetamine
- 9.1.10 Tirzepatide
- 9.2 ASEAN Anti-Obesity Drugs Market (2017-2032) by Drug Class
- 9.2.1 Market Overview
- 9.2.2 Market Overview
- 9.2.3 Amphetamine
- 9.2.4 GLP-1 receptor agonist
- 9.2.5 Lipase Inhibitor
- 9.3 ASEAN Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
- 9.3.1 Market Overview
- 9.3.2 Centrally Acting Drugs
- 9.3.3 Peripherally Acting Drugs
- 9.4 ASEAN Anti-Obesity Drugs Market (2017-2032) by Route of Administration
- 9.4.1 Market Overview
- 9.4.2 Oral
- 9.4.3 Subcutaneous
- 9.5 ASEAN Anti-Obesity Drugs Market (2017-2032) by Prescription Type
- 9.5.1 Market Overview
- 9.5.2 Prescription Drugs
- 9.5.3 Over The Counter Drugs
- 9.6 ASEAN Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
- 9.6.1 Market Overview
- 9.6.2 Hospital Pharmacies
- 9.6.3 Drug Store & Retail Pharmacies
- 9.6.4 Online Pharmacies
- 10 Australia Anti-Obesity Drugs Market (2017-2032)
- 10.1 Australia Anti-Obesity Drugs Market (2017-2032) by Drugs
- 10.1.1 Market Overview
- 10.1.2 Semaglutide
- 10.1.3 Phentermine/Topiramate
- 10.1.4 Naltrexone/Bupropion
- 10.1.5 Liraglutide
- 10.1.6 Gelesis 100
- 10.1.7 Orlistat
- 10.1.8 Phentermine
- 10.1.9 Methamphetamine
- 10.1.10 Tirzepatide
- 10.2 Australia Anti-Obesity Drugs Market (2017-2032) by Drug Class
- 10.2.1 Market Overview
- 10.2.2 Market Overview
- 10.2.3 Amphetamine
- 10.2.4 GLP-1 receptor agonist
- 10.2.5 Lipase Inhibitor
- 10.3 Australia Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
- 10.3.1 Market Overview
- 10.3.2 Centrally Acting Drugs
- 10.3.3 Peripherally Acting Drugs
- 10.4 Australia Anti-Obesity Drugs Market (2017-2032) by Route of Administration
- 10.4.1 Market Overview
- 10.4.2 Oral
- 10.4.3 Subcutaneous
- 10.5 Australia Anti-Obesity Drugs Market (2017-2032) by Prescription Type
- 10.5.1 Market Overview
- 10.5.2 Prescription Drugs
- 10.5.3 Over The Counter Drugs
- 10.6 Australia Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
- 10.6.1 Market Overview
- 10.6.2 Hospital Pharmacies
- 10.6.3 Drug Store & Retail Pharmacies
- 10.6.4 Online Pharmacies
- 11 India Anti-Obesity Drugs Market (2017-2032)
- 11.1 India Anti-Obesity Drugs Market (2017-2032) by Drugs
- 11.1.1 Market Overview
- 11.1.2 Semaglutide
- 11.1.3 Phentermine/Topiramate
- 11.1.4 Naltrexone/Bupropion
- 11.1.5 Liraglutide
- 11.1.6 Gelesis 100
- 11.1.7 Orlistat
- 11.1.8 Phentermine
- 11.1.9 Methamphetamine
- 11.1.10 Tirzepatide
- 11.2 India Anti-Obesity Drugs Market (2017-2032) by Drug Class
- 11.2.1 Market Overview
- 11.2.2 Market Overview
- 11.2.3 Amphetamine
- 11.2.4 GLP-1 receptor agonist
- 11.2.5 Lipase Inhibitor
- 11.3 India Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
- 11.3.1 Market Overview
- 11.3.2 Centrally Acting Drugs
- 11.3.3 Peripherally Acting Drugs
- 11.4 India Anti-Obesity Drugs Market (2017-2032) by Route of Administration
- 11.4.1 Market Overview
- 11.4.2 Oral
- 11.4.3 Subcutaneous
- 11.5 India Anti-Obesity Drugs Market (2017-2032) by Prescription Type
- 11.5.1 Market Overview
- 11.5.2 Prescription Drugs
- 11.5.3 Over The Counter Drugs
- 11.6 India Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
- 11.6.1 Market Overview
- 11.6.2 Hospital Pharmacies
- 11.6.3 Drug Store & Retail Pharmacies
- 11.6.4 Online Pharmacies
- 12 Regulatory Framework
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Funding and Investment Analysis
- 14.1 Analysis by Funding Instances
- 14.2 Analysis by Type of Funding
- 14.3 Analysis by Funding Amount
- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
- 15.1 Analysis by Partnership Instances
- 15.2 Analysis by Type of Partnership
- 15.3 Analysis by Leading Players
- 15.4 Analysis by Geography
- 16 Supplier Landscape
- 16.1 Market Share by Top 5 Companies
- 16.2 VIVUS Inc
- 16.2.1 Financial Analysis
- 16.2.2 Product Portfolio
- 16.2.3 Demographic Reach and Achievements
- 16.2.4 Mergers and Acquisitions
- 16.2.5 Certifications
- 16.3 Pfizer, Inc.
- 16.3.1 Financial Analysis
- 16.3.2 Product Portfolio
- 16.3.3 Demographic Reach and Achievements
- 16.3.4 Mergers and Acquisitions
- 16.3.5 Certifications
- 16.4 Novo Nordisk
- 16.4.1 Financial Analysis
- 16.4.2 Product Portfolio
- 16.4.3 Demographic Reach and Achievements
- 16.4.4 Mergers and Acquisitions
- 16.4.5 Certifications
- 16.5 Bayer AG
- 16.5.1 Financial Analysis
- 16.5.2 Product Portfolio
- 16.5.3 Demographic Reach and Achievements
- 16.5.4 Mergers and Acquisitions
- 16.5.5 Certifications
- 16.6 F Hoffmann-La Roche
- 16.6.1 Financial Analysis
- 16.6.2 Product Portfolio
- 16.6.3 Demographic Reach and Achievements
- 16.6.4 Mergers and Acquisitions
- 16.6.5 Certifications
- 16.7 Glaxosmithkline
- 16.7.1 Financial Analysis
- 16.7.2 Product Portfolio
- 16.7.3 Demographic Reach and Achievements
- 16.7.4 Mergers and Acquisitions
- 16.7.5 Certifications
- 16.8 Arena Pharmaceuticals
- 16.8.1 Financial Analysis
- 16.8.2 Product Portfolio
- 16.8.3 Demographic Reach and Achievements
- 16.8.4 Mergers and Acquisitions
- 16.8.5 Certifications
- 16.9 Eisai Co. Ltd
- 16.9.1 Financial Analysis
- 16.9.2 Product Portfolio
- 16.9.3 Demographic Reach and Achievements
- 16.9.4 Mergers and Acquisitions
- 16.9.5 Certifications
- 16.10 Takeda Pharmaceutical Company
- 16.10.1 Financial Analysis
- 16.10.2 Product Portfolio
- 16.10.3 Demographic Reach and Achievements
- 16.10.4 Mergers and Acquisitions
- 16.10.5 Certifications
- 16.11 Nalpropion Pharmaceuticals Inc
- 16.11.1 Financial Analysis
- 16.11.2 Product Portfolio
- 16.11.3 Demographic Reach and Achievements
- 16.11.4 Mergers and Acquisitions
- 16.11.5 Certifications
- 17 Asia Pacific Anti-Obesity Drugs Market – Distribution Model (Additional Insight)
- 17.1 Overview
- 17.2 Potential Distributors
- 17.3 Key Parameters for Distribution Partner Assessment
- 18 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 19 Company Competitiveness Analysis (Additional Insight)
- 19.1 Very Small Companies
- 19.2 Small Companies
- 19.3 Mid-Sized Companies
- 19.4 Large Companies
- 19.5 Very Large Companies
- 20 Payment Methods (Additional Insight)
- 20.1 Government Funded
- 20.2 Private Insurance
- 20.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.